BASF Boosts Bioagriculture
26 March, 2002 by Daniella GoldbergAustralia's biotechnology industry may be in for a big boost after a team from BASF, an international plant and chemical company, visited to find potential collaborative ventures.
Hep C treatment targeted
25 March, 2002 by Tanya HollisThe US subsidiary of homegrown drug discovery group Biota Holdings has announced plans to focus on treatments for hepatitis C virus.
Bioprospecting company on the move
22 March, 2002 by Pete YoungBioProspect is expanding its beachead in Queensland on the back of promising results from its five-month-old biota mining agreement with the State Government.
Metabolic in iron drug deal
21 March, 2002 by Melissa TrudingerMelbourne biotechnology company Metabolic Pharmaceuticals (ASX:MBP) has entered into licence and research agreements with Sydney's Heart Research Institute (HRI) to develop a drug for the treatment of iron overload diseases.
Skin doctor joins tanning tech company
21 March, 2002 by Tanya HollisA leading dermatologist has joined the board of the Australian company behind a new tanning drug.
Australian research makes a play in the post-genomic era
20 March, 2002 by Melissa TrudingerIn the biggest party the science community has ever seen, Australia was a wallflower.
Norwood makes a deal with Monash
19 March, 2002 by Tanya HollisImmunology therapies group Norwood Abbey has announced a research agreement with Monash University to develop and market its thymic manipulation technologies.
New pro-GM booklet launched
18 March, 2002 by Melissa TrudingerA booklet addressing gene technology issues was launched this week by Agrifood Awareness Australia - an industry alliance dedicated to increasing public awareness of gene technology.
EpiTan basks in glow of positive human trial results
18 March, 2002 by Tanya HollisAn Australian-made tanning drug has shown positive results in its first human trials.
Agenix dilutes stake in Singapore subsidiary
18 March, 2002 by Pete YoungListed Australian diagnostics biotech Agenix Ltd is diluting its stake in Singapore subsidiary PhytoProtein Biotech.
Tasmania wary of former GM sites
15 March, 2002 by Melissa TrudingerFormer GM crop field trial sites in Tasmania are under close scrutiny from the Tasmanian Department of Primary Industries, Water and Environment.
Biotech outshines in stocks review
15 March, 2002 by Tanya HollisBiotechnology emerged as the star performer in a Pricewaterhouse Coopers review of the life sciences sector.
Plant centre will allow new research
15 March, 2002 by Melissa TrudingerResearchers have welcomed the establishment of a new Plant Culture Facility (PCF) at ANU's Research School of Biological Sciences (RSBS).
Antisense reports loss in lead-up to MS trial
15 March, 2002 by Tanya HollisAustralia's newest listed biotechnology company, Antisense Therapeutics (ASX:ANP), today recorded a first-half loss of $1.6 million as it prepares for a pre-clinical study of its multiple sclerosis therapy.
Gradipore R&D, marketing push offset sales revenue increase
14 March, 2002 by Iain ScottA 75 per cent boost in sales revenues at Sydney biological separations company Gradipore was offset by continued heavy commitments in R&D and international expansion in its half-year results, released today.
